An introduction to the Marburg virus vaccine consortium, MARVAC
2022; Public Library of Science; Volume: 18; Issue: 10 Linguagem: Inglês
10.1371/journal.ppat.1010805
ISSN1553-7374
AutoresRobert W. Cross, Ira M. Longini, Stephan Becker, Karin Bok, David Boucher, Miles W. Carroll, Janet Dı́az, William E. Dowling, Ruxandra Draghia‐Akli, James T. Duworko, John M. Dye, Michael A. Egan, Patricia Fast, Amy Finan, Courtney L. Finch, Thomas R. Fleming, Joan Fusco, Thomas W. Geisbert, Anthony Griffiths, Stephan Günther, Lisa E. Hensley, Anna N. Honko, Ruth Hunegnaw, Jocelyn Jakubik, Julie E. Ledgerwood, Kerstin Lühn, Demetrius Matassov, Jeffrey Meshulam, Emily V. Nelson, Christopher L. Parks, Roxana Rustomjee, David Safronetz, Lauren M. Schwartz, Dean Smith, Paul Smock, Ydrissa Sow, Christina F. Spiropoulou, Nancy J. Sullivan, Kelly L. Warfield, Daniel Wolfe, Courtney Woolsey, Roland Zahn, Ana María Henao-Restrepo, César Muñoz‐Fontela, Andrea Marzi,
Tópico(s)COVID-19 epidemiological studies
ResumoThe emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine “MARVAC” consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.
Referência(s)